Mononucleosis Diagnostic Market

SKU: DM2195 | Last Updated On: Sep 06 2022 | Available Formats

> Mononucleosis Diagnostic Market Expected to reach a high CAGR of 4.9% By 2028: DataM Intelligence

Mononucleosis Diagnostic Market is segmented By Test Type (Epstein Barr Virus (EBV) Antibody Test, Monospot Test, Complete Blood Count Test), By End-User (Hospitals, Laboratories, others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Mononucleosis Diagnostic Market is expected to grow at a CAGR of 4.9% during the forecasting period (2021-2028).

Mononucleosis Diagnostic Market Scope

Metrics

Details

Market CAGR

4.9%

Segments Covered

By Test Type, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get a Free sample click here

Mono, or mononucleosis, is an acute infectious disease caused by the Epstein-Barr virus (EBV). People with mononucleosis often have a high fever, Laryngitis, hepatosplenomegaly, abnormal lymphocyte, and others. Most cases of mono are mild and can be treated easily. Adolescents and young adults (12 to 40 years old) are more likely to be affected. There are various detection tests used for the diagnosis of mononucleosis such as the complete blood count test, monospot test, and Epstein Barr virus (EBV) antibody test.

Market Dynamics

The global mononucleosis diagnostic market is growing owing to several factors including rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM treatment.

Rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM treatment are expected to drive market growth.

The rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research & development activities for IM diagnosis and treatment are the major factors that are increasing the global mononucleosis diagnostic market.

Various novel technological advancements are taking place that can diagnose the infection faster as compared to already present in the market. For instance, in 2020, Roche announced that the USFDA has approved the Cobas EBV test that is the 1st in-vitro quantitative diagnostic test in US for the diagnosis of EBV Epstein-Barr Virus. This is very huge success for the healthcare industry and professionals as now it will be easy to monitor the patients at risk from this virus as it will conduct high number of tests in small duration of time.

Increasing adolescent population globally is also one of the major factors leading to growth of the market as mononucleosis is most common among teens and adults. More than half of all adolescents globally live in Asia. South Asia has nearly 350 million adolescents than any other region. It is followed by East Asia and the Pacific with over 300 million. The adolescent population of either of these regions are dwarfs that of any other region in the world. According to World Health Organization (WHO) report, there are nearly 1.2 billion adolescents (10-19 years old) worldwide. In some countries, adolescents account for a quarter of the population and the number of adolescents is expected to rise through 2050, mainly in low- and middle-income countries (LMICs) where close to 90% of 10- to 19-year-olds live.

Limitations of available tests for the diagnosis of mononucleosis is expected to hamper the market growth.

There are some limitations associated with mononucleosis diagnostic tests which are expected to hamper the market's growth over the forecast period. There are only three tests that can diagnose mononucleosis and that is very low in regard to the rate by which the infectious mononucleosis is growing.

Global Mononucleosis Diagnostic Market - Industry Analysis

The global mononucleosis diagnostic market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs

Segment Analysis

Monospot Test segment is expected to hold the largest market share in global mononucleosis diagnostic market

On the basis of test type, the mononucleosis diagnsotic market is segmented into Epstein Barr Virus (EBV) antibody test, monospot test, and complete blood count test. Among these, the monospot test segment accounted for the largest market share, owing to the several benefits associated with this test, such as accurate results, non-interference with other tests, cost-effectiveness, rapid detection of antibodies, among others. A monospot test is a quick screening test to detect a type of antibody (heterophil antibody) that forms during certain infections. This test is also used in the detection of other diseases with similar symptoms, such as cytomegalovirus infection, HIV, and strep throat. In this test, a blood sample is placed on a microscope slide and mixed with other substances. If heterophil antibodies are present, then the blood clumps (agglutinates), and indicates a mono infection. Monospot testing can usually detect antibodies 2 to 9 weeks after a person is infected. It typically is not used to diagnose mono that started more than 6 months earlier. Also, increase in awareness and knowledge regarding the disease are expected to drive the growth of this segment over the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mononucleosis diagnostic market

North America is dominating the global mononucleosis diagnostic market, and is expected to hold the highest market share over the forecast period, owing to rising incidence rate of infectious mononucleosis (IM), advancement in healthcare infrastructure supporting novel testing, and increasing research and development activities by major players in this region. Majority of the younger people in United States are infected with mononucleosis. According to the United States Census Bureau, there were 41,910,114 people aged between 10-19 in the United States, which is approx. 13% of the total population. Hence, with rising adolescent population this region, the market of mononucleosis diagnostic is growing rapidly.

On the other hand, the Asia-Pacific mononucleosis diagnostic market is growing at the fastest growth rate over the forecast period, owing to the rising adolescent population in this region.  According to the UNICEF data, over half of all adolescents across the world live in Asia, and South Asia is home to the largest number of adolescents in any region in the world (around 340 million).  South Asia is followed by East Asia and the Pacific, with around 277 million. Hence, due to increasing number of adolescents, huge opportunities are estimated to drive the growth of the market during the forecast period.

Competitive Landscape

The global mononucleosis diagnostic market is highly competitive with presence of smaller and major players. Some of the major players in the market include: Bio-Rad Laboratories Inc., Thermo Fischer Scientific Inc., Abbott Laboratories, Cardinal Health Inc., Arlington Scientific Inc., Quidel Corporation, Beckman Coulter Inc., Immunostics Inc., Meridian Bioscience, Sekisui Diagnostics, among others.

The key players are adopting various growth strategies such as Test Type launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the mononucleosis diagnostic market globally. For instance, in September 2019, Roche launched two tests, for use on the automated cobas 6800/8800 Systems in countries accepting the CE mark. The cobas EBV (Epstein-Barr virus) and cobas BKV (BK virus) Tests provide reliable, standardized, high-quality results for clinical decision-making to help manage the risk of infection and improve the management of severely immunocompromised transplant patients.

In July 2019, NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, launched CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), which can cause infectious mononucleosis and other illnesses.

Global Mononucleosis Diagnostic Market – Key Companies to Watch

Bio-Rad Laboratories

Overview: Bio-Rad Laboratories is an American company that develops and manufactures various products with technological advancements for Clinical Diagnostics and Life Science research. It was founded in 1952 and is headquartered in Berkeley, California. This company operates worldwide.

Product Portfolio: PLATELIA™ EB-NA-1 IgG: This product is used for the detection of IgG and IgM antibodies that are specific to the EBV antigen. Platelia EBV EIA microplate technology is widely used for detection of infectious mononucleosis.

Key Developments: In Mar 2021, Bio-Rad Laboratory revealed its partnership with F. Hoffmann-La Roche AG

The global mononucleosis diagnostic market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Oligonucleotide Therapy Market

Oligonucleotide Synthesis Market

Tumor Necrosis Factor Inhibitor Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest